Pathology & Laboratory Medicine

Publications

Filter By Faculty

Filter by Principal Investigator

2022

Cyrta J, Rosiene J, Bareja R, Kudman S, Zoughbi WA, Motanagh S, et al. Whole-genome characterization of myoepithelial carcinomas of the soft tissue. Cold Spring Harb Mol Case Stud. 2022;8(7).

Magro CM, Mo JH, Telang G. Localized lymphomatoid papulosis: Unilesional lymphomatoid papulosis, regional lymphomatoid papulosis, and persistent agmination of lymphomatoid papulosis. Clin Dermatol. 2022;40(6):622-638.

Tsui DC, Aisner D, Nijmeh H, Bao L, Menter A, D Camidge R. Tumor Shrinkage With Combination of Alectinib and Trastuzumab in a Patient With ALK-Rearranged Non-small Cell Lung Cancer Harboring HER2-Amplification as an Acquired Resistance Mechanism to ALK Inhibitor Therapy. Clin Lung Cancer. 2022;23(2):e99-e103.

Anderson KC, Cantley LC, Dalla-Favera R, Van Dang C, Diaz LA, DuBois RN, et al. The AACR Journals: Advancing Progress Toward the AACR's 115-Year Mission. Cancer Prev Res (Phila). 2022;15(11):705-712.

Gao X, Wang Y, Ribeiro CF, Manokaran C, Chang H, Von T, et al. Blocking PI3K p110β Attenuates Development of PTEN-Deficient Castration-Resistant Prostate Cancer. Mol Cancer Res. 2022;20(5):673-685.

Bychkovsky BL, Li T, Sotelo J, Tayob N, Mercado J, Gomy I, et al. Identification and Management of Pathogenic Variants in BRCA1, BRCA2, and PALB2 in a Tumor-Only Genomic Testing Program. Clin Cancer Res. 2022;28(11):2349-2360.

Devereaux KA, Souers RJ, Merker JD, Lindeman NI, Graham RP, Hameed MR, et al. Clinical Testing for Tumor Cell-Free DNA. Arch Pathol Lab Med. 2022.

Devereaux KA, Souers RJ, Graham RP, Portier BP, Surrey LF, Yemelyanova A, et al. Neoplastic Cellularity Assessment in Molecular Testing. Arch Pathol Lab Med. 2022;146(9):1062-1071.

Parra-Herran C, Khani F, Wobker SE. Gender distribution of editors and authors of reference textbooks in anatomic pathology: further edits are required. Mod Pathol. 2022;35(12):1784-1790.

Alilou M, Khorrami M, Prasanna P, Bera K, Gupta A, Viswanathan VS, et al. A tumor vasculature-based imaging biomarker for predicting response and survival in patients with lung cancer treated with checkpoint inhibitors. Sci Adv. 2022;8(47):eabq4609.